Inventor · disambiguated record
Helmut Salih
Also filed as: SALIH HELMUT
7 granted patents·10 pending applications·5 citations·filing 2004–2025
75Inventor score
Files withDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS6DEUTSCHES KREBSFORSCH4PROBIOCON GMBH3UNIV EBERHARD KARLS2DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS1
Top patents by PatentIndex Score
17 records- 0178US11612646B2PSMA binding antibody and uses thereofDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2017·Granted Mar 28, 2023·2 cites·8 claims
- 0274US10906952B2Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15Ra and therapeutic uses thereofDEUTSCHES KREBSFORSCH·Filed 2016·Granted Feb 2, 2021·3 cites·15 claims
- 0374US2025346669A1Psma binding antibody and uses thereofDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2025·Application pending·0 cites
- 0473US12398208B2PSMA binding antibody and uses thereofDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2022·Granted Aug 26, 2025·0 cites·5 claims
- 0567US2025197510A1Anti-FLT3 Antigen Binding ProteinsDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2024·Application pending·0 cites
- 0660US12048744B2RANKL-specific agent for treating metastatic diseasePROBIOCON GMBH·Filed 2020·Granted Jul 30, 2024·0 cites·12 claims
- 0759US2022324931A1FUSION PROTEINS COMPRISING A BINDING PROTEIN AND AN INTERLEUKIN-15 POLYPEPTIDE HAVING A REDUCED AFFINITY FOR IL15Ra AND THERAPEUTIC USES THEREOFDEUTSCHES KREBSFORSCH·Filed 2021·Application pending·0 cites
- 0854US12195543B2Anti-FLT3 antigen binding proteinsDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS·Filed 2019·Granted Jan 14, 2025·0 cites·11 claims
- 0954US2021163564A1FUSION PROTEINS COMPRISING A BINDING PROTEIN AND AN INTERLEUKIN-15 POLYPEPTIDE HAVING A REDUCED AFFINITY FOR IL15Ra AND THERAPEUTIC USES THEREOFDEUTSCHES KREBSFORSCH·Filed 2020·Application pending·0 cites
- 1050US2023406961A1Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodiesDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2021·Application pending·0 cites
- 1149US10806786B2RANKL-specific agent for treating metastatic diseasePROBIOCON GMBH·Filed 2015·Granted Oct 20, 2020·0 cites·16 claims
- 1246US2023007977A1Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereofDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2020·Application pending·0 cites
- 1340US7939266B2Treatment of transformed or infected biological cellsUNIV EBERHARD KARLS·Filed 2004·Granted May 10, 2011·0 cites·5 claims
- 1437US2008069772A1Treatment of transformed or infected biological cellsUNIV EBERHARD KARLS·Filed 2007·Application pending·0 cites
- 1534US2017362325A1Use of blocking-reagents for reducing unspecific t cell-activationDEUTSCHES KREBSFORSCH·Filed 2015·Application pending·0 cites
- 1633US2019218302A1Anti-cancer combination treatmentPROBIOCON GMBH·Filed 2017·Application pending·0 cites
- 1731US2018208657A1Recombinant antibody molecule and its use for target cell restricted t cell activationUNIV WUERZBURG J MAXIMILIANS·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Helmut Salih files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →